Examples of using Pegfilgrastim in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Because it is pegylated in pegfilgrastim, the rate at which the medicine is removed from the body is decreased, allowing the medicine to be given less often.
Pegfilgrastim appears to be mainly eliminated by neutrophil mediated clearance,
The study showed non-inferiority of 6 mg lipegfilgrastim to 6 mg pegfilgrastim for the primary endpoint,
If you are hypersensitive(allergic) to pegfilgrastim, filgrastim, E. coli derived proteins,
neutrophils produced in response to pegfilgrastim show normal
Do not use Neulasta if you are allergic to pegfilgrastim, filgrastim, or any of the other ingredients of this medicine.
healthy volunteers treated with pegfilgrastim and 121 patients treated with placebo was performed.
withdrawal of filgrastim and pegfilgrastim.
Generally, events of glomerulonephritis resolved after dose reduction or withdrawal of filgrastim and pegfilgrastim.
Patients were randomised 1:1 to receive 6 mg lipegfilgrastim or 6 mg pegfilgrastim.
The elimination of pegfilgrastim is non-linear with respect to dose; serum clearance of pegfilgrastim decreases with increasing dose.
The pharmacokinetics of pegfilgrastim were studied in 37 paediatric patients with sarcoma, who received 100 μg/kg pegfilgrastim after the completion of VAdriaC/IE chemotherapy.
each containing 6 mg pegfilgrastim.
Associated with a clinical diagnosis of febrile neutropenia was lower in the pegfilgrastim group tn.
Δ LS mean(least square mean difference lipegfilgrastim- pegfilgrastim) and CI out of multivariate Poisson regression analysis.
Pegfilgrastim did not affect reproductive performance
Limited clinical data suggest a similar effect on time to recovery of severe neutropenia for pegfilgrastim to filgrastim in patients with de novo acute myeloid leukaemia see section 5.1.
The incidence of hospitalisations and IV anti-infective use associated with a clinical diagnosis of febrile neutropenia was lower in the pegfilgrastim group compared with placebo 1% versus 14%, p 0.001; and 2% versus 10%, p 0.001.
Limited clinical data suggest a comparable effect on time to recovery of severe neutropenia for pegfilgrastim to filgrastim in patients with de novo acute myeloid leukaemia see section 5.1.
The incidence of hospitalisations and IV anti-infective use associated with a clinical diagnosis of febrile neutropenia was lower in the pegfilgrastim group compared with placebo 1% versus 14%,
